Purchasing Pyrilutamide for hair loss treatment in India, and exploring the possibility of utilizing Minoxidil, Finasteride, and RU58841 as alternatives.
A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).
The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.
A user experienced significant hair loss despite using Dutasteride and RU58841 for three years, questioning the effectiveness of these treatments. They are considering a scalp biopsy to explore other potential causes of hair loss.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
The conversation is about finding 1.5mm cartridges for a Dr. Pen device, with a preference for purchasing through Amazon. The discussion does not mention specific hair loss treatments like Minoxidil, finasteride, or RU58841.
RU58841 powder is being discussed as a hair loss treatment, with concerns about its legitimacy and safety when purchased from Amazon. The conversation also mentions Minoxidil as a comparison in terms of price.
The conversation discusses the potential availability of GT20029 for hair loss treatment, with one user noting promising Phase 1 results and inquiring about gray market access. Another user humorously suggests it will take 50 years to become available.
The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.
PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.
A new potential hair loss treatment called HMI-115, and the cost of this treatment which may be expensive due to production costs but could be competitive with other treatments such as hair transplants.
The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.
RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.
RU58841 helped regrow hairline without side effects for a bodybuilder using PEDs. The treatment included RU58841, finasteride, minoxidil, GKH-Cu, microneedling, and HGH.
Treatment options for female alopecia androgenetica, discussing the availability of spironolactone online in The Netherlands and other potential treatments like finasteride, minoxidil and RU58841.
The user noticed potential hair growth after 13 days of using RU58841, alongside a regimen of oral minoxidil, finasteride, and topical minoxidil. Others think it's too soon to see results, and some are surprised by the high dosage of oral minoxidil.
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.
The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.
RU58841 is discussed as a hair loss treatment, with users considering lower doses like 2.5% to reduce costs. Some users suggest that if already blocking DHT, lower doses might still be effective unless there's high sensitivity to DHT.
Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.
The conversation discusses using RU58841 at a 2% concentration as an alternative due to side effects from finasteride. The user plans to start with a lower concentration and increase if necessary.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user is also interested in purchasing a high-quality red light cap for hair growth.
The user plans to switch to oral finasteride and oral minoxidil due to insufficient results from PRP, topical minoxidil, and mild DHT inhibitors. They seek advice on purchasing these medications from My.India, questioning its trustworthiness.